Dr. Hambleton has served as a member of our board of directors since August 2018. Dr. Hambleton served as Interim President & CEO, Arch Oncology, a private company, from August 2020 to March 2021. From June 2018 until her retirement in April 2020, Dr. Hambleton served as Senior Vice President, Chief Medical Officer, Head of Development at IDEAYA Biosciences, an oncology medicine company. From September 2017 to May 2018 and from March 2016 to May 2016, Dr. Hambleton served as an independent strategic consultant for various life sciences companies. From May 2016 to September 2017, she served as Vice President, Head U.S. Medical at Bristol-Myers Squibb, a global biopharmaceutical company. From August 2015 to February 2016, Dr. Hambleton served as Executive Vice President, Chief Medical Officer at Five Prime Therapeutics, a biotechnology company, and as Senior Vice President, Chief Medical Officer from December 2012 to August 2015. From April 2010 to November 2012, Dr. Hambleton served as Vice President, Clinical Development at Clovis Oncology, and from 2003 to 2010, Dr. Hambleton held increasing roles of responsibility in BioOncology at Genentech. Dr. Hambleton has served on the board of directors of SpringWorks Therapeutics, a biopharmaceutical company, since May 2020 and Erasca, Inc., a biotechnology company, since March 2021. Dr. Hambleton completed her hematology-oncology training at the University of California, San Francisco, where she then served on the faculty from 1993 to 2003. Dr. Hambleton received an M.D. from Case Western Reserve University School of Medicine and a B.S. in Nursing from Duke University and was board-certified in Hematology and Internal Medicine.

Dr. Harler joined IGM in 2021. She is our Chief Executive Officer and a member of our Board of Directors. Prior to joining IGM she was Senior Vice President, Head of Immunology and Fibrosis Development at Bristol Myers Squibb, where she oversaw late-stage development of assets for the potential treatment of psoriasis, inflammatory bowel disease (IBD) and nonalcoholic steatohepatitis (NASH), among others. Dr. Harler also oversaw approved medicines within the immunology and fibrosis portfolios, such as Orencia and Zeposia. In her more than 10 years at Bristol Myers Squibb she also served as Head of Innovative Medicines Development and Head of Innovative Clinical Development in the cardiovascular, fibrosis, immunoscience and genetically-defined diseases group. Prior to joining Bristol Myers Squibb, Dr. Harler worked in both medical affairs and clinical research at Wyeth Pharmaceuticals (now part of Pfizer). Dr. Harler received a B.S. from Wheeling University in West Virginia and an M.D. from Marshall University. She completed training as a general surgeon at Brown University’s Rhode Island Hospital, where she was also a research fellow with a focus on the role of immune cells in wound healing.

Mr. Lee has served as a member of our board of directors since July 2019. Mr. Lee has served as Co-Founder and Portfolio Manager at Redmile Group, an investment advisory firm since 2007. Prior to Redmile, Mr. Lee worked as a biotechnology investor at Steeple Capital, an investment management firm, and as an analyst at Welch Capital Partners, an investment advisory firm, and Prudential Equity Group, a financial services company. Mr. Lee has served on the board of directors of Fate Therapeutics, a biopharmaceutical company, since July 2018 and Shattuck Labs, a biotechnology company, since June 2020. Mr. Lee holds a B.S. in Molecular and Cellular Biology from the University of Arizona.

Dr. Strohl has served as a member of our board of directors since August 2018. In August 2016, Dr. Strohl founded BiStro Biotech Consulting, a biotechnology consulting company, of which he also serves as President. From February 2016 to August 2016, Dr. Strohl served as Vice President and Biologics Fellow at Janssen BioTherapeutics, the therapeutic biologics organization within the Janssen Research & Development division of Johnson & Johnson, a multinational medical devices and pharmaceutical company, and served as its Vice President and Head from October 2013 to February 2016. Prior to that, from April 2008 to October 2013, Dr. Strohl served as Head of Antibody Discovery at Janssen BioTherapeutics. Dr. Strohl has also held various roles at Merck, a pharmaceutical company, including leading Natural Products Biology and leading Biologics discovery efforts and was a Professor in the Department of Microbiology and the Program of Biochemistry at The Ohio State University. Dr. Strohl received a B.S. in Biology from Central Michigan University and a Ph.D. in Microbiology from Louisiana State University.

Dr. Thompson has served as a member of our board of directors since October 2023. Dr. Thompson is currently Executive Vice President of Research and Development, Rare Disease at Amgen.  At the time of its acquisition by Amgen, Dr. Thompson served as the Executive Vice President of Research and Development of Horizon Therapeutics. During her time at Horizon, Dr. Thompson played an important role in the transformation of Horizon into a science-based biopharma company, establishing and growing an R&D function comprising scientists and technical experts across research, translational sciences, clinical development, clinical operations, biometrics, PV and safety, regulatory affairs, project and program management, R&D strategy and external innovation. She also played a key role in the acquisition and integration of Viela Bio as well as the expedited filing and approval of TEPEZZA®, including its successful FDA Advisory Committee meeting. Prior to Horizon, Dr. Thompson held roles of increasing seniority and scope at AbbVie, Raptor, InterMune and Amgen in a career spanning clinical development, business development and medical communications. Dr. Thompson has served as a member of the board of California Life Sciences, a life sciences membership organization and was named to the PharmaVoice 100 list in 2023 and the Healthcare Businesswomen’s Association Luminary list in 2021.  Dr. Thompson received a Ph.D. in Macromolecular and Cellular Structure and Chemistry from the Scripps Research Institute and a B.S. in Chemistry from Harvey Mudd College.

 

Ms. Topsøe has served as a member of our board of directors since August 2018, and previously served as an observer on our board of directors beginning in 2013. Since March 2013, Ms. Topsøe has served on the board of directors of Haldor Topsøe A/S, and has served on the board of directors of Topsøe Holding A/S, its holding company, since June 2015. Ms. Topsøe previously was a lawyer at Allen & Overy LLP and Simpson Thacher and Bartlett LLP. Ms. Topsøe pursued a B.A. in Chinese Studies from the University of Copenhagen, studied Chinese Language and Literature at Peking University, and received an LL.B. from the University of London and an M.B.A. from London Business School and Columbia Business School.

Mr. Topsøe has served as a member of our board of directors since August 2018. Since June 2015, Mr. Topsøe has served as Chairman of the board of directors of Topsøe Holding A/S, and has served on the board of directors of Haldor Topsøe A/S, a Danish catalysis and chemical processing company and a subsidiary of Topsøe Holding A/S, since October 2010 and as its Vice Chairman since August 2016. Since January 2009, Mr. Topsøe has served as Partner at AMBROX Capital, a Danish investment management firm, and as Associate Partner since September 2016. From 1996 to 2008, Mr. Topsøe was employed in various functions within Alfred Berg/ABN Amro Bank including Head of Equities, Denmark. Mr. Topsøe served as a member of the board of directors of Motortramp, a Danish provider of marine transportation services, and Dampskibsselskabet Orients Fond, a Danish charitable foundation, from 2017 to October 2020. Mr. Topsøe received a Graduate Diploma in Business Administration (Finance) from the Copenhagen Business School.

Dr. Ahmed is a virologist and immunologist, and an internationally recognized expert on T cell survival, function and the development of immunological memory. He is a Director of the Emory Vaccine Center; Charles Howard Candler Professor of Microbiology and Immunology, Emory University School of Medicine. His work includes discoveries related to how immune memory cells are created, how long they survive and how factors such as IL-2 and IL-15 relate to these responses within different microenvironments within an organism and the relationship between chronic viral infection and ongoing immunity. His work impacts the development of therapeutics in infectious disease, particularly in the setting of viral infection and viral persistence to cancer and cancer immunology. Dr. Ahmed is the author or co-author of more than 300 peer-reviewed articles, has received numerous awards, including the William B. Coley Award in 2017 and is a member of the National Academy of Sciences. Dr. Ahmed received his Ph.D. degree in microbiology from Harvard University. Before coming to Emory, he was a Professor at the University of California, Los Angeles School of Medicine.

Dr. Davis is one of the world’s leading authorities on T cell recognition. His research focuses on how T cells and B cells recognize antigen and behave following such interactions. This includes the structural and biochemical underpinnings of T cell receptor binding and signal transduction and the dynamics of molecular movement at the T cell/antigen-presenting cell interface, in both preclinical models and humans. His discoveries include identifying the T-cell receptor gene, development of peptide-MHC tetramers to study T cell populations capable of recognizing particular targets and elucidation and quantification of specific events at the immunologic synapse required for T cell function. Dr. Davis is the author or co-author of more than 300 peer-reviewed articles and books, is a member of the National Academy of Sciences, and is the recipient of numerous awards and distinctions, including the William B. Coley Award in 2000. Dr. Davis received his B.A. degree in molecular biology from Johns Hopkins University and his Ph.D. degree in molecular biology from the California Institute of Technology. He was a postdoctoral fellow at the Laboratory of Immunology at the National Institutes of Health prior to joining Stanford.

Dr. Freeman is renowned for his work characterizing the PD-L1/PD-1 interaction and elucidating the functional impact of inhibiting this interaction on T cells in health and disease. Dr. Freeman’s research identified the ligands for the major pathways that control the immune response by inhibiting T cell activation or stimulating T cell activation. He showed that engagement of PD-1 by PD-L1 or PD-L2 inhibited T cell activation, cytokine production, and cytolytic activity whereas blockade enhanced these activities. Dr. Freeman’s work led directly to the development of a successful strategy for cancer immunotherapy: block the pathways that tumors use to turn off the immune response. Dr. Freeman has published over 300 scientific papers and holds over 50 US patents on immunotherapies. He has received numerous awards, including the William B. Coley Award for Distinguished Research in Tumor Immunology in 2014 and the Warren Alpert Foundation Prize for the discovery and development of PD-1 pathway blockade in 2017. Dr. Freeman received his Ph.D. degree in 1979 from Harvard University and was a postdoctoral fellow at Harvard prior to joining the Dana Farber Cancer Institute.